From July 19, 2024 until July 20, 2024
Ym Munich - Holiday Inn Munich - Canol y Ddinas, Bafaria, yr Almaen
Postiwyd gan Treganna Fair Net
https://www.esmo.org/meeting-calendar/esmo-congress-2023
categorïau: Gofal Iechyd a Fferyllol
Hits: 1826
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Rydych chi'n defnyddio fersiwn hŷn o'ch porwr gwe, felly efallai na fydd rhai nodweddion yn arddangos yn iawn.
GOFYNION LLEIAF: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
Mae OncologyPRO bellach yn cynnig adnoddau cyfarfod: +3.000 o sleidiau a gweddarllediadau; crynodebau ac eBosteri.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Gohebydd Dyddiol177Lu PSMA-617 yn gwella rPFS ar gyfer cleifion canser y prostad sy'n gallu gwrthsefyll sbaddu metastatig ac sy'n naïf taxane23 Hyd 2023Mae canfyddiadau treial PSMAfore wedi'u cyfyngu gan y ffaith nad ydynt yn dangos budd o ran OS.